Russia's Covid-19 vaccine rollout receives wary, mixed response

Representational image.

While excitement and enthusiasm greeted the Western-developed coronavirus vaccine when it was rolled out, the Russian-made version has received a mixed response, with reports of empty Moscow clinics that offered the shot to health care workers and teachers the first members of the public designated to receive it.

Kremlin officials and state-controlled media touted the Sputnik V vaccine as a major achievement after it was approved August 11. But among Russians, hope that the shot would reverse the course of the COVID-19 crisis has become mixed with wariness and scepticism, reflecting concerns about how it was rushed out while still in its late-stage testing to ensure its effectiveness and safety.

Russia faced international criticism for approving a vaccine that hasn't completed advanced trials among tens of thousands of people, and experts both at home and abroad warned against its wider use until the studies are completed.

Despite those warnings, authorities started offering it to certain high-risk groups, such as front-line medical workers, within weeks of approval. Alexander Gintsburg, head of the Gamaleya Institute that developed the vaccine, said last week over 150,000 Russians have gotten it.

One recipient was Dr Alexander Zatsepin, an ICU specialist in Voronezh, a city 500 kilometres south of Moscow, who received the vaccine in October.

We've been working with COVID-19 patients since March, and every day when we come home, we worry about infecting our family members. So when some kind of opportunity to protect them and myself appeared, I thought it should be used, he said.

But Zatsepin said he still takes precautions against infection because studies of the vaccine's effectiveness aren't over.

There is no absolute confidence yet, he said.

After Britain announced on December 2 it had approved a vaccine developed by drugmakers Pfizer and BioNTech, President Vladimir Putin told authorities to start a large-scale inoculation campaign, a sign of Moscow's eagerness to be at the front of the race against the pandemic.

Russia approved its vaccine after it was tested on only a few dozen people, touting it as the first in the world to receive a go-ahead. Developers named it Sputnik V, a reference to the Soviet Union's 1957 launch of the world's first satellite during the Cold War.

More than just national pride is at stake. Russia has recorded more than 2.7 million cases of COVID-19, and over 48,000 deaths, and it wants to avoid another damaging lockdown of its economy.

On December 2, Putin cited a target of over 2 million doses in the coming days. Despite such a limited supply for a nation of 146 million, Moscow immediately widened who was eligible for it. Shots are free to everyone in medical or educational facilities, both state and private; social and municipal workers; retail and service workers; and those in the arts.

The European Medicines Agency said it has not received a request from the vaccine makers to consider licensing it for use in the EU, but some data have been shared with the World Health Organisation. The UN agency does not typically approve vaccines itself but waits for regulatory agencies to weigh in first. The Russian vaccine is reportedly under consideration for use in a global effort led by WHO to distribute COVID-19 vaccines to poorer countries.

Unlike in the UK, where the first shots are going to the elderly, Sputnik V is going to those aged 18 to 60 who don't have chronic illnesses and aren't pregnant or breastfeeding.

Its developers have said study data suggests the vaccine was 91% effective, a conclusion based on 78 infections among nearly 23,000 participants. That's far fewer cases than Western drugmakers have accumulated during final testing before analysing their candidates' efficacy, and important demographic and other details from the study have not been released.

A poll conducted in October by the Levada Centre, Russia's top independent pollster, showed that 59% of Russians were unwilling to get the shots even if offered for free.

Denis Volkov, sociologist and deputy director of the Levada Center, says respondents cited unfinished clinical trials, saying the vaccine was raw and they were suspicious of the claims that Russia was the first country to have a vaccine while others were still working on theirs.

Some medical workers and teachers interviewed by The Associated Press expressed scepticism about the vaccine because it hasn't been fully tested.

Moscow Mayor Sergei Sobyanin said more than 6,000 people received the shots in the first five days of vaccinations launched on December 5. But some media reports about the first days of the Moscow campaign showed empty clinics and medical workers offering the shots to anyone who walked in. In some instances, this was because the vaccine must be stored at minus 18 degrees Celsius and each vial contains five doses. Once defrosted, it must be administered within two hours or discarded.

The rollout outside Moscow and the surrounding region appeared to go much slower, with Health Minister Mikhail Murashko declaring that all regions started the vaccination on December 15.

Media reports suggested there may be problems with scaling up the manufacture and distribution of Sputnik V. It uses two different adenovirus vectors for the two-shot regimen, which complicates production. In addition, the low-temperature storage and transport makes it harder to move across the vast country. There also were confused signals about whether recipients should consume alcohol.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel